/ 0
Table of contents

Document in text mode:

(2022) 34 SAcLJ 1 (Published on e-First 24 June 2022) THE PATENT LINKAGE SCHEME FOR PHARMACEUTICALS IN SINGAPORE: ASSESSMENT AND SUGGESTIONS FOR REFORMSince 2004, Singapore adopted the patent linkage scheme from the US to meet its obligations under the US–Singapore Free Trade Agreement. The patent linkage scheme requires a generic drug manufacturer that wishes to obtain a licence from the Health Science Authority to notify the patent holder of its application. If the generic licence applicant files a Category B application, claiming invalidity or non-infringement of the patent, the patent holder may, within 45 days of being notified, initiate an infringement proceeding that will trigger a 30-month moratorium against marketing approval of the applicant’s drug. While the patent linkage scheme has generally been well received in the US, the form of the patent linkage scheme in Singapore is significantly different – Singapore has modified its version of the scheme to be more pro-patentee. ...